58°
Cloudy
FRI
 59°
 52°
SAT
 59°
 47°
SUN
 57°
 48°
MON
 60°
 45°
TUE
 58°
 47°

FDA halts Amgen study after teen patient death

  • FILE - This April 20, 2010 file photo, shows the exterior view of Amgen Inc. in Fremont, Calif. U.S. government health regulators announced Tuesday, Feb. 26, 2013, that they have halted Amgen's studies of its thyroid drug Sensipar after the death of a 14-year-old patient in a company trial. (AP Photo/Paul Sakuma, file)

WASHINGTON — Federal health regulators have halted Amgen's studies of its drug Sensipar after the death of a 14-year-old patient in a company trial.

The Food and Drug Administration said Tuesday it is still gathering information about the death, but has shut down all studies of the drug in children.

Sensipar is approved in adults to treat over-activity of the parathyroid gland, which can lead to brittle bones, kidney stones and abdominal pain. It has been used since 2004 to treat symptoms of chronic kidney disease and parathyroid cancer.

Amgen Inc. had been studying the drug to see whether it works in children.

The Thousand Oaks, Calif.-based company said in a statement that it "is working as rapidly as possible to understand the circumstances of what happened."


© The Press Democrat |  Terms of Service |  Privacy Policy |  Jobs With Us |  RSS |  Advertising |  Sonoma Media Investments |  + |  Place an Ad
Switch to our Mobile View